649 related articles for article (PubMed ID: 37121515)
21. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
22. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies.
Biagi E; Marin V; Giordano Attianese GM; Dander E; D'Amico G; Biondi A
Haematologica; 2007 Mar; 92(3):381-8. PubMed ID: 17339188
[TBL] [Abstract][Full Text] [Related]
23. Combining precision oncology and immunotherapy by targeting the MALT1 protease.
Mempel TR; Krappmann D
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36270731
[TBL] [Abstract][Full Text] [Related]
24. Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
Tapia-Galisteo A; Álvarez-Vallina L; Sanz L
J Hematol Oncol; 2023 Jul; 16(1):83. PubMed ID: 37501154
[TBL] [Abstract][Full Text] [Related]
25. Neoantigens - the next frontier in precision immunotherapy for B-cell lymphoproliferative disorders.
Sabdia MB; Patch AM; Tsang H; Gandhi MK
Blood Rev; 2022 Nov; 56():100969. PubMed ID: 35570070
[TBL] [Abstract][Full Text] [Related]
26. T-cell-based immunotherapy in colorectal cancer.
Feng M; Zhao Z; Yang M; Ji J; Zhu D
Cancer Lett; 2021 Feb; 498():201-209. PubMed ID: 33129958
[TBL] [Abstract][Full Text] [Related]
27. Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies.
Falchi L
Curr Hematol Malig Rep; 2017 Oct; 12(5):484-494. PubMed ID: 28822058
[TBL] [Abstract][Full Text] [Related]
28. Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia.
Knaus HA; Kanakry CG; Luznik L; Gojo I
Curr Drug Targets; 2017; 18(3):315-331. PubMed ID: 25981611
[TBL] [Abstract][Full Text] [Related]
29. An overview of cancer immunotherapeutic strategies.
Wahid B; Ali A; Rafique S; Waqar M; Wasim M; Wahid K; Idrees M
Immunotherapy; 2018 Aug; 10(11):999-1010. PubMed ID: 30149763
[TBL] [Abstract][Full Text] [Related]
30. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
Li F; Zhang T; Cao L; Zhang Y
Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
[TBL] [Abstract][Full Text] [Related]
31. Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy.
Chowdhury PS; Chamoto K; Honjo T
J Intern Med; 2018 Feb; 283(2):110-120. PubMed ID: 29071761
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Grigor EJM; Fergusson DA; Haggar F; Kekre N; Atkins H; Shorr R; Holt RA; Hutton B; Ramsay T; Seftel M; Jonker D; Daugaard M; Thavorn K; Presseau J; Lalu MM
BMJ Open; 2017 Dec; 7(12):e019321. PubMed ID: 29288188
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy for cancer treatment.
Donátová K; Nováková E; Šupolíková M
Klin Onkol; 2022; 35(4):284-289. PubMed ID: 35989085
[TBL] [Abstract][Full Text] [Related]
34. Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy.
Klepsch V; Hermann-Kleiter N; Baier G
Immunol Lett; 2016 Oct; 178():31-6. PubMed ID: 26992368
[TBL] [Abstract][Full Text] [Related]
35. Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy.
Fan Y; Moon JJ
Vaccines (Basel); 2015 Aug; 3(3):662-85. PubMed ID: 26350600
[TBL] [Abstract][Full Text] [Related]
36. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
37. The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.
Wang Y; Zhang H; He YW
Front Immunol; 2019; 10():1574. PubMed ID: 31379815
[TBL] [Abstract][Full Text] [Related]
38. Nanobodies targeting immune checkpoint molecules for tumor immunotherapy and immunoimaging (Review).
Yu S; Xiong G; Zhao S; Tang Y; Tang H; Wang K; Liu H; Lan K; Bi X; Duan S
Int J Mol Med; 2021 Feb; 47(2):444-454. PubMed ID: 33416134
[TBL] [Abstract][Full Text] [Related]
39. Nucleic Acid Immunotherapeutics for Cancer.
Shen T; Zhang Y; Zhou S; Lin S; Zhang XB; Zhu G
ACS Appl Bio Mater; 2020 May; 3(5):2838-2849. PubMed ID: 33681722
[TBL] [Abstract][Full Text] [Related]
40. Personalized Immuno-Oncology.
Jain KK
Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]